Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343294 | 0.81 | MEN1 (0.36) | MEN1KMT2AALDH1A1CYP3A4AAK1 | |
| SCHEMBL31256560 | 0.81 | MEN1 (0.36) | MEN1KMT2AALDH1A1CYP3A4AAK1 | |
| SCHEMBL15864693 | 0.77 | CYP1A2 (0.41) | MEN1KMT2AALDH1A1CYP3A4AAK1 | |
| SCHEMBL2767403 | 0.76 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL1958391 | 0.73 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1CYP3A4AAK1 | |
| SCHEMBL15770392 | 0.72 | MEN1 (0.49) | MEN1KMT2AALDH1A1CYP3A4AAK1 | |
| SCHEMBL30997911 | 0.72 | MEN1 (0.40) | MEN1KMT2AALDH1A1CYP3A4AAK1 | |
| SCHEMBL25302744 | 0.72 | PDE7A (0.38) | ALDH1A1CYP3A4MAPK1CTSBTSHR | |
| SCHEMBL690072 | 0.69 | GPR35 (0.42) | MEN1KMT2AALDH1A1CYP3A4AAK1 | |
| SCHEMBL20594965 | 0.69 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1CYP3A4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689393-A4 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| EP-1689393-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005037198-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | MEN1 2783/4885KMT2A 2695/4885ALDH1A1 4524/4885 |
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | MEN1 2732/4885KMT2A 826/4885ALDH1A1 2956/4885 |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | TNK2, CDC42BPB, CDC42BPA | MEN1 2126/4885KMT2A 2508/4885ALDH1A1 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.